<DOC>
	<DOCNO>NCT00622739</DOCNO>
	<brief_summary>This 6 week , open-label , blinded-rater , randomize , control , pilot study design determine dosing , safety efficacy ziprasidone treatment pediatric bipolar disorder ( PBD ) . In pilot study compare efficacy rapid versus slow dose titration ziprasidone PBD . The investigator hypothesize subject ziprasidone monotherapy reduction manic symptom . Also , investigator hypothesize slow titration ziprasidone result less side effect assist medication compliance measure patient report pill count .</brief_summary>
	<brief_title>Ziprasidone Pediatric Bipolar Disorder</brief_title>
	<detailed_description>This study enroll approximately 60 child adolescent age 10-17 year diagnose bipolar disorder . Their participation last 8 week ( 2 week screen 6 week medication management ) enrollment last two year . After screen period , subject meet inclusion/exclusion criterion randomize either rapid slow dose titration ziprasidone . Subjects rapid titration group reach maximum dose study drug 2 week , subject slow titration group 4 week . The study doctor may deviate dose schedule clinically indicate . The primary data analysis pilot study examine effect rapid- versus slow-dose titration ziprasidone manic symptom .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Outpatients age 1017 year Currently meet Diagnostic Statistical Manual Mental Disorders IVText Revision ( DSMIVTR ) criteria bipolar disorder , type I , II Not Otherwise Specified ( NOS ) determine Schedule Affective Disorders Schizophrenia Present/Lifetime ( KiddieSADSPL ) Experiencing manic , hypomanic mixed state determine clinical diagnosis Kiddie Young Mania rating scale ( KYMRS ) equal 14 General good health determine medical history , physical examination , laboratory evaluation Female adolescent , sexually active , must practice birth control method approve primary investigator Ability swallow tablet Subject 's parent guardian must fully capable monitoring subject 's disease process compliance treatment Parent ( ) legal guardian ( ) must read sign informed consent form nature study fully explain assent must obtain subject . Have lifetime DSMIVTR Axis I disorder diagnosis autistic disorder , schizophrenia , schizoaffective disorder , psychotic disorder DSMIVTR diagnosis alcohol substance abuse dependence within past 6 month Serious unstable medical neurological condition require concomitant medication Judged principal investigator ( PI ) acutely suicidal homicidal , imminent risk injure self others cause significant damage propertyâ€”i.e. , subject need inpatient facility Known suspect intelligence quotient ( IQ ) less 70 Have DSMIVTR diagnosis anorexia and/or bulimia time screen within last six month Female pregnant nursing Subjects history syncopal episode ( sudden loss consciousness loss postural tone precede presyncopal phase ) unexplained loss consciousness Subjects history significant cardiovascular disease significant concurrent cardiovascular disease , include uncontrolled hypertension , hypotension , congestive heart failure congenital heart disease Subjects history cardiac arrhythmia , conduction abnormality know personal history correct QT prolongation ( include congenital long QT syndrome ) Subjects know genetic risk QT syndrome determine family history first degree relative Subjects take medication know interact ziprasidone subject take medication consistently observe prolong QT interval Subjects clinically significant ECG abnormality screen Subjects persistent QTc ( Fridericia ) * 460 msec screen Screening laboratory value outside normal range judge clinically significant investigator Patients family Spanish speaking exclude study instrument use study validate Spanish</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Treatment</keyword>
</DOC>